Lipocine Inc. 4
4 · Lipocine Inc. · Filed Jan 30, 2017
Insider Transaction Report
Form 4
Lipocine Inc.LPCN
Mattila Jyrki
Chief Business Officer
Transactions
- Award
Restricted Stock Unit
2017-01-26+15,000→ 15,000 totalExercise: $0.00From: 2017-12-31Exp: 2027-01-25→ Common Stock (15,000 underlying)
Footnotes (2)
- [F1]Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit
- [F2]Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of LPCN 1021.